Insights › Science & technology › November 19, 2026
Science & technology · Pipeline & development

Lipid nanoparticle-delivered Cas13b ribonucleoproteins targeting survivin overcome gemcitabine resistance in pancreatic cancer

bioRxiv (Pharmacology) Published: Preprint

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, largely due to its poor response to chemotherapy and the development of drug resistance. Survivin (BIRC5), an inhibitor of apoptosis frequently overexpressed in PDAC, contributes to tumor cell survival and gemcitabine resistance, making it an attractive therapeutic target. Here, we developed a lipid nanoparticle (LNP)-ba

Original source
Read the source — biorxiv.org ↗

We link to the original publisher. The summary above is a short guide; read the original for the full details.

More in Science & technology

See everything in Science & technology →

Look into this further

Read every record in your own language

This page shows the three newest items per field. Members see every record in the field, in 109 languages, with the search engines that work on them.

Read it all — start from $3No app-store installation. Cancel any time.